CTNM
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ · Healthcare · Biotechnology · US
$16.70
−4.95%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 32.36x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.62x
- Price / sales
- —
- Price / cash flow
- -11.85x
Enterprise value
- Enterprise value
- $398.3M
- EV / sales
- —
- EV / EBITDA
- -6.04x
- EV / EBIT
- -6.00x
- Market cap
- $628.3M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026